The history of Sildenafil presents a challenging picture for shareholders. While the initial release generated massive returns, the end of its patent opened the floodgates to generic alternatives, dramatically reducing sales. This poses a unique risk for pharmaceutical companies relying on related blockbuster products, suggesting that a unquestioni

The story of Viagra, and its creator copyright, presents a complex case study for investors. Initially a blockbuster drug, yielding billions in revenue , its patent expiration created a flood of generic competition , significantly eroding its position . While some pharmaceutical companies may try to capitalize on similar conditions , the existing l